Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)- RFA-PS-23-002, Enhancing Telehealth Strategies To Support Retention and Adherence to Antiretroviral Therapy (ART), and RFA-PS-23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living With HIV Who Are Disproportionately Affected; Amended Notice of Closed Meeting

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

April 17, 2023

Issuing agencies

Health and Human Services DepartmentCenters for Disease Control and Prevention

Full Text

<html>
<head>
<title>Federal Register, Volume 88 Issue 73 (Monday, April 17, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 73 (Monday, April 17, 2023)]
[Notices]
[Page 23428]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-07996]



[[Page 23428]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP)-- RFA-PS-23-002, Enhancing Telehealth Strategies 
To Support Retention and Adherence to Antiretroviral Therapy (ART), and 
RFA-PS-23-003, Exploring Preferences for Long-Acting Antiretroviral 
Therapies (LA-ART) in a Community-Based Sample of Priority Populations 
Living With HIV Who Are Disproportionately Affected; Amended Notice of 
Closed Meeting

    Notice is hereby given of a change in the meeting of the Disease, 
Disability, and Injury Prevention and Control Special Emphasis Panel 
(SEP)-- RFA-PS23-002, Enhancing Telehealth Strategies to Support 
Retention and Adherence to Antiretroviral Therapy (ART), and RFA-PS23-
003, Exploring Preferences for Long-Acting Antiretroviral Therapies 
(LA-ART) in a Community-Based Sample of Priority Populations Living 
with HIV Who are Disproportionately Affected; May 11-12, 2023, 10 
a.m.--5 p.m., EDT, teleconference, Centers for Disease Control and 
Prevention, 8 Corporate Boulevard, Room 1077, Atlanta, Georgia 30329, 
in the original Federal Register Notice. The meeting was published in 
the Federal Register on March 8, 2023, Volume 88, Number 45, page 
14370.
    The meeting is being amended to remove RFA-PS23-002, Enhancing 
Telehealth Strategies to Support Retention and Adherence to 
Antiretroviral Therapy (ART) and to remove the second day of the 
meeting. The notice should read as follows:
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)--RFA-PS23-003, Exploring 
Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a 
Community-Based Sample of Priority Populations Living with HIV Who are 
Disproportionately Affected.
    Date: May 11, 2023.
    Time: 10 a.m.-5 p.m., EDT.
    The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H., 
Scientific Review Officer, National Center for HIV, Viral Hepatitis, 
STD, and TB Prevention, Centers for Disease Control and Prevention, 
1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329-4027. 
Telephone: (404) 718-8833; Email: <a href="/cdn-cgi/l/email-protection#cc8b8da2a8a9bebfa3a28cafa8afe2aba3ba"><span class="__cf_email__" data-cfemail="c08781aea4a5b2b3afae80a3a4a3eea7afb6">[email&#160;protected]</span></a>.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-07996 Filed 4-14-23; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on April 17, 2023.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.